LIFEWORKS
8.9.2021 11:02:06 CEST | Business Wire | Press release
LifeWorks, a leading provider of digital and in-person total wellbeing solutions, has announced the acquisition of Ascender, a leading psychological services provider in the field of employee health and wellbeing.
Key highlights of the acquisition include:
- Headquartered in the Netherlands, Ascender’s highly experienced team of 38 employees and approximately 40 freelancers will join LifeWorks and continue to operate out of its 25 locations across the Netherlands, with existing clients seeing their services continue uninterrupted.
- As Ascender is integrated into LifeWorks global operations, it will operate in the Netherlands on a largely standalone basis, servicing clients throughout the Benelux region.
- Ascender operated first as a combination of network partners 25 years ago and merged to become Ascender in 2009. It is one of the most respected providers in the corporate wellbeing market in the Netherlands and has a strong roster of approximately 150 clients with an average tenure of 10 years.
- The acquisition will leverage the skills, knowledge and experience Ascender’s teams and services that include psychological services related to health@work, employee assistance programmes, counselling, and training through a team of highly credentialed psychologists, while giving Ascender access to LifeWorks clinical best practices, digital technology and worldwide presence.
- With Ascender’s strong track record of growth, local knowledge and clinical expertise, the move will allow LifeWorks to continue to expand its total wellbeing solutions to domestic European markets, and harness its existing relationships with insurance providers, hospitals and care companies as well as (multi)nationals working out of the Netherlands post-Brexit.
Comments from Philip Mullen, managing director, United Kingdom and Europe at LifeWorks:
“Throughout the pandemic we have witnessed a huge appetite amongst multinationals and local companies to support the total wellbeing of employees that are now spread across the world. The acquisition of Ascender will not only strengthen our presence in this region, but in addition, given Ascender offers a full suite of clinical expertise and research, our hope is that the company’s insight on psychological wellbeing can further enhance our customer offering on a global level.”
Comments from Moniek Vossenaar, managing director, Ascender:
“Joining LifeWorks represents an important step for Ascender’s growth, the services we provide and the opportunities for our employees. The companies have a shared goal to improve the total wellbeing of our clients’ employees, and shared values of long-term relationships, treating others the way we want to be treated, and being innovative and entrepreneurial. We’re positive this acquisition will be beneficial to both companies and all parties involved.”
This acquisition represents approximately one per cent of LifeWorks revenue and is not expected to have a material impact on the company’s financial performance in 2021.
About LifeWorks
LifeWorks is a world leader in providing digital and in-person solutions that support the total wellbeing of individuals. We deliver a personalised continuum of care that helps our clients improve the lives of their people and by doing so, improve their business.
About Ascender
Founded in 2009, Ascender is one of the top three players in the corporate wellness market in the Netherlands and has a strong roster of approximately 150 clients with an average tenure of 10 years. Headquartered in the Netherlands, Ascender hash 25 locations across the country, 38 employees and approximately 40 freelancers. The company offers psychological services related to health@work, EFAP, counselling, and training/coaching through a team of psychologists, on a fee for service basis.
ID-CORP, ID-MH, ID-UK
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005404/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
